Since the first Kloster Seeon meeting on β-secretases in 2013, a handful of BACE inhibitors have entered clinical trials and researchers have learned more about what these proteases do in development and adulthood. What’s the status of the field in the fall of 2016? Check out our coverage of the 2nd Kloster Seeon meeting. Highlights include conditional BACE1 knockouts, updates on non-APP substrates cleaved by BACE, news about BACE’s role in dystrophic neurites, assays to measure off-target effects and—finally—the arrival of BACE1-selective inhibitors.
Despite concerns over potential side effects, researchers seem more enthusiastic than ever about the prospect of treating Alzheimer’s with β-secretase inhibitors.
Researchers at the Kloster Seeon meeting pressed in on the question of what are the physiological functions of this protease after development is complete.
At the 2nd Kloster Seeon meeting on BACE proteases, researchers linked BACE substrates to regulation of synaptic activity.
In Seeon, researchers reported that blocking the protease may heal dystrophic neurites and repair electrical activity.
Despite no warning signs in ongoing clinical trials, researchers are searching for safer drugs, and better biomarkers to measure what they do.